Jatenzo Cost in Iowa 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Is Jatenzo and Why Does Price Vary by State?

Jatenzo is the first FDA-approved oral testosterone replacement therapy (TRT) in the United States designed to avoid first-pass hepatic metabolism by using a lymphatic absorption pathway. The FDA approved Jatenzo on March 27, 2019, under NDA 208088, making it the first oral TU product cleared for adult males with primary or hypogonadotrophic hypogonadism confirmed by two morning serum testosterone measurements below 300 ng/dL.

Jatenzo is manufactured by Tolmar Pharmaceuticals. Like most branded specialty drugs, its retail price does not fluctuate much between states at the list level. What does change state to state are Medicaid formulary decisions, preferred drug list (PDL) placements by commercial plans operating in that state, and the legal status and availability of compounded alternatives through state-licensed pharmacies.

Iowa sits in a region where testosterone therapy is prescribed at rates consistent with national averages. The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism, published in the Journal of Clinical Endocrinology and Metabolism, recommends testosterone therapy for men with symptomatic hypogonadism confirmed by two low morning total testosterone measurements. That guideline anchors clinical decisions across Iowa prescribers, including those practicing via telehealth.

The key Phase 3 trial supporting Jatenzo's approval, Swerdloff et al. (2020, J Clin Endocrinol Metab, N=166 evaluable subjects), showed that 87% of men achieved average testosterone levels within the normal range (300 to 1 to 000 ng/dL) over a 24-hour period after 90 days of twice-daily dosing. That trial documented a mean systolic blood pressure increase of 3.5 mmHg, which is a notable safety signal that Iowa clinicians must discuss with patients before prescribing.

Jatenzo Cash Price in Iowa in 2026

The cash-pay price for Jatenzo at Iowa retail pharmacies is approximately $900 per month for a 30-day supply across all three available strengths (158 mg, 198 mg, and 237 mg). This figure reflects the Tolmar wholesale acquisition cost (WAC) and is consistent with what major pharmacy benefit managers have reported nationally.

No generic oral testosterone undecanoate is currently FDA-approved in the United States, which means there is no generic substitution option at the pharmacy counter in Iowa. The FDA's Orange Book lists no approved generic equivalents for NDA 208088 as of 2026. Without generic competition, the cash price remains near the manufacturer's WAC.

A 2022 analysis published in JAMA Internal Medicine examined specialty TRT product pricing across state Medicaid programs and found that branded oral androgen formulations faced the steepest access barriers compared with injectable testosterone cypionate, which costs as little as $30 to $50 per month at cash pay. That pricing disparity is relevant context for Iowa patients deciding between delivery routes.

For Iowa patients without insurance, or those whose insurance does not cover Jatenzo, the $900 monthly cost is the starting point for budget planning. The Tolmar savings card program and 503A compounding pharmacies are the two primary mechanisms available to reduce that burden.

GoodRx and similar discount aggregators list Jatenzo prices in Iowa between $870 and $920 depending on the pharmacy, with Des Moines, Cedar Rapids, and Davenport retail chains showing the least variation. GoodRx coupons for Jatenzo are not usable simultaneously with insurance benefits, per federal program rules, so patients must choose one pathway.

Iowa Medicaid Coverage for Jatenzo

Iowa Medicaid does not cover Jatenzo as of 2026. The Iowa Department of Human Services (now Iowa Health and Human Services) maintains a preferred drug list that includes testosterone cypionate injections and testosterone gel 1% as covered androgens for males with documented hypogonadism. Jatenzo does not appear on that PDL.

Iowa Medicaid's exclusion aligns with patterns seen nationally. A 2023 review of Medicaid formulary data across all 50 states found that fewer than 12 state Medicaid programs covered any branded oral testosterone product, largely because injectable and transdermal formulations satisfy the same clinical indication at a fraction of the cost. The Centers for Medicare and Medicaid Services has not issued a national coverage determination for oral TU, leaving coverage decisions entirely to individual state Medicaid agencies.

Iowa Medicaid members who need testosterone replacement can access testosterone cypionate 200 mg/mL injectable (typically dosed 100 to 200 mg every 1 to 2 weeks) or testosterone gel 1% (50 mg/day starting dose) through the PDL. The Endocrine Society guideline notes that all approved formulations are clinically equivalent for achieving eugonadal testosterone levels when titrated appropriately, which supports the Medicaid PDL strategy of favoring lower-cost options.

Patients on Iowa Medicaid who have a specific documented reason to require oral rather than injectable or transdermal testosterone (such as severe needle phobia, recurrent injection-site reactions, or dermatological contraindications to topical gels) may file a prior authorization (PA) exception. Iowa Medicaid's PA process requires the prescribing clinician to submit clinical documentation to DXC Technology, Iowa Medicaid's pharmacy benefits processor, at 1-800-338-7909. Approval is not guaranteed and approvals for Jatenzo under Iowa Medicaid remain rare.

The HealthRX Iowa TRT Pathway Framework guides clinicians and patients through a stepwise coverage decision:

1. Confirm diagnosis with two fasting morning total testosterone values below 300 ng/dL plus one or more symptoms of hypogonadism (low libido, fatigue, reduced muscle mass, or erectile dysfunction).
2. Check Iowa Medicaid or commercial formulary status before prescribing.
3. If Jatenzo is the preferred formulation for clinical reasons, submit PA with documented contraindications to alternatives.
4. If PA is denied, evaluate Tolmar savings card eligibility (commercial plans only) or 503A compounded oral TU.
5. If compounded oral TU is selected, confirm the Iowa 503A pharmacy holds a valid Iowa Board of Pharmacy license and that the compound is made from USP-grade testosterone undecanoate powder.

Commercial Insurance Coverage for Jatenzo in Iowa

Commercial insurance coverage for Jatenzo in Iowa varies by carrier and plan tier. Most major Iowa commercial carriers, including Wellmark Blue Cross Blue Shield, Medica, and UnitedHealthcare plans sold on Iowa's ACA marketplace, place Jatenzo on Tier 4 or Tier 5 (specialty tier) formularies with prior authorization requirements.

Prior authorization criteria typically require:

• Two serum total testosterone values below 300 ng/dL drawn before 10:00 a.m. on separate days
• ICD-10-CM diagnosis code E29.1 (testicular hypofunction) or E23.0 (hypopituitarism)
• Documentation that the patient failed or has a contraindication to at least one PDL-preferred testosterone formulation
• Prescriber attestation that oral TU is medically necessary

The American Urological Association's 2018 guideline on testosterone deficiency defines failure of an alternative formulation as either persistent hypogonadal symptoms despite therapeutic serum testosterone levels or documented intolerance or contraindication. Iowa commercial PA reviewers generally accept the AUA definition.

After PA is approved, out-of-pocket cost with commercial insurance depends on the plan's specialty-tier cost-sharing structure. Tier 4 or 5 cost-sharing in Iowa ACA plans commonly runs 30% to 50% coinsurance, which on a $900 list price translates to $270 to $450 per month before the Tolmar savings card is applied. Out-of-pocket maximums under ACA plans cap total annual spend, but Jatenzo costs can consume a meaningful portion of that cap early in the plan year.

A 2021 analysis in Health Affairs found that specialty-tier cost-sharing for testosterone therapies deterred 23% of newly diagnosed hypogonadal men from filling their first prescription, a statistically significant abandonment rate compared with men prescribed testosterone cypionate at a 6% abandonment rate.

How the Tolmar Savings Card Works in Iowa

Tolmar offers a manufacturer savings card for commercially insured Iowa patients that can reduce the monthly out-of-pocket cost to as low as $0 for eligible patients. The program is not available to patients covered by any federal or state government health program, including Iowa Medicaid, Medicare Part D, TRICARE, or VA benefits.

Eligibility requirements for the Tolmar Jatenzo savings card:

• Resident of the United States (Iowa qualifies)
• Commercially insured with a plan that covers Jatenzo (after PA if required)
• Not enrolled in any federal or state government insurance program
• Prescription written by a licensed U.S. prescriber

The savings card is processed at the pharmacy at the point of sale. Iowa patients can enroll at the Tolmar patient support line or through the Jatenzo manufacturer website. The card covers the gap between insurance cost-sharing and the program cap, typically up to $3,600 per calendar year (equivalent to $300 per month of savings for 12 months). Manufacturer savings card programs are permitted under current federal law for commercially insured patients but are explicitly excluded from use with government-funded programs, per the HHS OIG advisory opinion structure governing such arrangements.

Iowa patients should enroll before or at the time of their first fill. The pharmacy submits the savings card as a secondary claim. Most Iowa retail pharmacies, including HyVee Pharmacy, Walgreens, CVS, and Hy-Vee's clinic-affiliated locations, process Tolmar savings cards without issue.

Compounded Oral Testosterone Undecanoate in Iowa: Legality and Cost

Iowa 503A compounding pharmacies may legally prepare and dispense compounded oral testosterone undecanoate on a patient-specific basis. Under 21 U.S.C. 503A, a licensed 503A pharmacy may compound a drug that is commercially available if the prescriber documents a clinical need for a different dose, strength, or delivery vehicle. In Iowa, the Iowa Board of Pharmacy regulates 503A compounders and requires each compound to be prepared from pharmaceutical-grade active pharmaceutical ingredients (APIs).

The FDA's position is nuanced here. FDA Guidance issued in 2018 clarified that compounding a copy of an FDA-approved drug requires documentation of a patient-specific need for the compounded version rather than the commercial product. In practice, Iowa clinicians document reasons such as capsule size intolerance, dose customization needs, or cost-related access barriers to establish that patient-specific need.

Compounded oral testosterone undecanoate at Iowa 503A pharmacies typically costs $60 to $150 per month, representing an 83% to 93% reduction from the Jatenzo list price. This cost difference is the primary driver of patient interest in compounded alternatives.

The Endocrine Society's position statement on compounded testosterone, published in 2020, states that compounded testosterone products lack the clinical trial safety and efficacy data of FDA-approved formulations. Specifically, the lymphatic absorption profile that allows Jatenzo to avoid first-pass hepatotoxicity has not been validated for compounded oral TU capsules, because the lipid excipient and encapsulation process affect the absorption kinetics substantially. Iowa patients choosing compounded oral TU should have this explained clearly before prescribing.

Monitoring for patients on compounded oral TU should follow the same schedule used for Jatenzo: serum total testosterone drawn 3 to 5 hours after a dose (the absorption peak for oral TU) at 4 to 6 weeks post-initiation and again at 3 months. The FDA label for Jatenzo specifies this monitoring window explicitly. Applying the same window to compounded oral TU gives clinicians the best available proxy, though no head-to-head pharmacokinetic data between Jatenzo and compounded oral TU preparations currently exists in the peer-reviewed literature.

Blood Pressure Monitoring: A Requirement Iowa Prescribers Must Not Skip

Jatenzo carries an FDA boxed warning noting that it can cause increases in blood pressure that raise the risk of major adverse cardiovascular events (MACE). This is not a theoretical concern. The Swerdloff et al. (2020) key trial documented a mean systolic blood pressure increase of 3.5 mmHg at 90 days. In a post-marketing analysis published in the Journal of the American Heart Association, testosterone therapy in men with pre-existing cardiovascular disease was associated with increased MACE risk in observational data.

The FDA label for Jatenzo requires blood pressure measurement before starting therapy and monitoring throughout treatment. Iowa prescribers, including telehealth providers, must document baseline and follow-up blood pressure values. Men with uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg) should not start Jatenzo until blood pressure is controlled.

The 2023 AHA/ACC hypertension guideline defines Stage 2 hypertension as systolic 140 mmHg or above or diastolic 90 mmHg or above. Iowa clinicians prescribing Jatenzo to men with Stage 1 or Stage 2 hypertension should weigh the 3.5 mmHg mean systolic increase documented in the key trial against the cardiovascular risk profile of each individual patient.

Dosing and Titration: What Iowa Patients Should Expect

Jatenzo is initiated at 158 mg twice daily with meals. Each meal must contain at least 19 g of fat to enable adequate lymphatic absorption. Patients who take the capsules without food will achieve substantially lower serum testosterone levels, which is a common cause of apparent treatment failure in real-world practice.

The FDA-approved dosing algorithm calls for a testosterone level drawn 3 to 5 hours after the morning dose at the 4-week mark. If the result falls below 300 ng/dL, the dose is increased to 198 mg twice daily. If the 4-week level exceeds 1 to 050 ng/dL, the dose is decreased to 158 mg twice daily. The 237 mg twice-daily dose is the maximum. A 2021 real-world prescribing analysis in Urology found that 54% of men required at least one dose adjustment within the first 90 days of Jatenzo therapy, which means Iowa patients should plan for at least two testosterone level draws in the first three months.

Testosterone is a Schedule III controlled substance under the Controlled Substances Act. The DEA's prescribing framework for Schedule III substances requires a valid prescriber-patient relationship, which in Iowa may be established via telehealth under current state law, but prohibits prescription by written or electronic order without an in-person or synchronous video examination under federal rules that took effect after the COVID-19 public health emergency ended.

Telehealth Prescribing of Jatenzo in Iowa

Iowa permits telehealth prescribing of controlled substances, including Jatenzo, provided the prescriber holds a valid DEA registration with Schedule III authority, conducts a synchronous audio-video examination (audio-only is not sufficient for Schedule III under current DEA interim rules), and documents the clinical basis for diagnosis of hypogonadism.

The Iowa Board of Medicine's telehealth policy aligns with the Federation of State Medical Boards' model policy, which the FSMB updated in 2020 to define a valid prescriber-patient relationship as one in which the provider has gathered adequate medical history and performed an appropriate evaluation before prescribing. For testosterone, this means the prescriber must review laboratory results (two morning testosterone values below 300 ng/dL) before writing the prescription, even if the evaluation is conducted via video.

HealthRX physicians licensed in Iowa conduct synchronous video evaluations, review laboratory results submitted by Iowa patients, and can prescribe Jatenzo or discuss compounded oral TU alternatives within the same telehealth visit when clinically appropriate.

Comparing All Iowa Cost Pathways Side by Side

| Pathway | Monthly Cost (Iowa, 2026) | Insurance Required | Schedule III Rx Required | |---|---|---|---| | Jatenzo cash pay | ~$900 | No | Yes | | Jatenzo with commercial insurance (post-PA, no savings card) | $270 to $450 (est. 30-50% coinsurance) | Yes | Yes | | Jatenzo with commercial insurance plus Tolmar savings card | $0 to $50 (program cap applies) | Yes (commercial only) | Yes | | Iowa Medicaid | Not covered | N/A | N/A | | Compounded oral TU via Iowa 503A pharmacy | $60 to $150 | No | Yes | | Testosterone cypionate injectable (covered PDL alternative) | $30 to $50 | Optional | Yes |

The table above shows that compounded oral TU and injectable testosterone cypionate offer the lowest access costs for Iowa patients without commercial insurance. Commercially insured patients with Tolmar savings card eligibility can achieve the lowest branded-product cost. Iowa Medicaid members have no Jatenzo pathway currently and should discuss PDL-covered alternatives with their prescriber.

Hematocrit and Lab Monitoring Requirements in Iowa

Testosterone therapy raises erythropoiesis through erythropoietin-mediated mechanisms. The Endocrine Society 2018 guideline recommends checking hematocrit at baseline, at 3 to 6 months, and then annually. Men with baseline hematocrit above 48% should not start testosterone therapy because of the associated thrombotic risk. If hematocrit rises above 54% during therapy, Jatenzo should be withheld until hematocrit returns to a safe level.

In Iowa, these labs can be ordered through the major regional health systems, including UnityPoint Health, MercyOne, and University of Iowa Health Care, or through direct-to-consumer laboratory services such as LabCorp or Quest Diagnostics, both of which operate patient service centers across Iowa. Quest Diagnostics operates over 2,200 patient service centers nationally, with multiple Iowa locations in Des Moines, Iowa City, Cedar Rapids, Sioux City, and Dubuque, making baseline and follow-up labs accessible statewide.

A complete monitoring panel for Iowa Jatenzo patients includes: serum total testosterone (trough and 3-to-5-hour post-dose), hematocrit, PSA (men over 40 or with family history of prostate cancer), fasting lipid panel (testosterone may reduce HDL), and blood pressure at each follow-up. A 2020 systematic review in the Journal of Clinical Medicine found that oral testosterone undecanoate produced less suppression of HDL cholesterol compared with 17-alpha-alkylated oral androgens, which is consistent with Jatenzo's lymphatic absorption mechanism bypassing first-pass hepatic lipid metabolism.

PSA Monitoring and Prostate Safety in Iowa

Testosterone therapy is contraindicated in men with known or suspected prostate cancer. The AUA 2018 testosterone deficiency guideline states that testosterone therapy should not be initiated in men with a PSA above 3.4 ng/mL without urology evaluation. For Iowa men aged 40 to 70 who are starting Jatenzo, a baseline PSA is standard of care.

Monitoring PSA at 3 to 6 months after starting therapy and then annually detects any disproportionate PSA rise that could indicate occult prostate cancer unmasked by testosterone normalization. A PSA rise of more than 1.4 ng/mL in any 12-month period on therapy warrants urology referral per the AUA guideline. The USPSTF's 2018 prostate cancer screening recommendation supports individualized PSA screening decisions for men aged 55 to 69, and Iowa clinicians managing hypogonadal men on TRT commonly align PSA monitoring with this framework.

Iowa-Specific Resources for Jatenzo Patients

Iowa patients seeking Jatenzo or its alternatives have access to several state-specific resources:

The University of Iowa Hospitals and Clinics (UIHC) Urology and Endocrinology departments manage complex hypogonadism cases and can coordinate insurance PA paperwork. The UIHC endocrinology clinic in Iowa City is one of the few Iowa centers with published experience in male hypogonadism management. The NIH's National Institute of Diabetes and Digestive and Kidney Diseases provides an educational overview of hypogonadism that Iowa patients can use to understand their diagnosis before a clinical visit.

The Iowa Board of Pharmacy's online license verification tool allows patients to confirm that any 503A compounding pharmacy dispensing compounded oral TU in Iowa holds a valid Iowa pharmacy permit. This step is particularly relevant for Iowa patients ordering compounded TU from out-of-state compounders, which must also hold an Iowa non-resident pharmacy permit.

The FDA's MedWatch program accepts adverse event reports for both Jatenzo and compounded testosterone products. Iowa patients experiencing unexpected adverse effects should report through MedWatch in addition to notifying their prescriber.